

Stephen A Ward

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8297119/publications.pdf>

Version: 2024-02-01

308
papers

15,251
citations

14655

66
h-index

32842

100
g-index

332
all docs

332
docs citations

332
times ranked

11544
citing authors

#	ARTICLE	IF	CITATIONS
1	Remdesivirâ€“ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2. International Journal of Antimicrobial Agents, 2022, 59, 106542.	2.5	7
2	Haematological consequences of acute uncomplicated falciparum malaria: a WorldWide Antimalarial Resistance Network pooled analysis of individual patient data. BMC Medicine, 2022, 20, 85.	5.5	9
3	<i>Wolbachia</i> depletion blocks transmission of lymphatic filariasis by preventing chitinase-dependent parasite exsheathment. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2120003119.	7.1	7
4	Dose prediction for repurposing nitazoxanide in SARSâ€“CoVâ€“2 treatment or chemoprophylaxis. British Journal of Clinical Pharmacology, 2021, 87, 2078-2088.	2.4	46
5	Therapeutic Potential of Nitazoxanide: An Appropriate Choice for Repurposing versus SARS-CoV-2?. ACS Infectious Diseases, 2021, 7, 1317-1331.	3.8	37
6	Enantioselective Synthesis and Profiling of Potent, Nonlinear Analogues of Antimalarial Tetraoxanes E209 and N205. ACS Medicinal Chemistry Letters, 2021, 12, 1077-1085.	2.8	5
7	Anti-Wolbachia drugs for filariasis. Trends in Parasitology, 2021, 37, 1068-1081.	3.3	27
8	Development of Pyrazolopyrimidine Anti- <i>Wolbachia</i> Agents for the Treatment of Filariasis. ACS Medicinal Chemistry Letters, 2021, 12, 1421-1426.	2.8	5
9	Co-transmission of Related Malaria Parasite Lineages Shapes Within-Host Parasite Diversity. Cell Host and Microbe, 2020, 27, 93-103.e4.	11.0	67
10	Longitudinal Pharmacokinetic-Pharmacodynamic Biomarkers Correlate With Treatment Outcome in Drug-Sensitive Pulmonary Tuberculosis: A Population Pharmacokinetic-Pharmacodynamic Analysis. Open Forum Infectious Diseases, 2020, 7, ofaa218.	0.9	11
11	M1 macrophage features in severe Plasmodium falciparum malaria patients with pulmonary oedema. Malaria Journal, 2020, 19, 182.	2.3	9
12	Prioritization of Antiâ€“SARSâ€“CoVâ€“2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics. Clinical Pharmacology and Therapeutics, 2020, 108, 775-790.	4.7	118
13	A novel fluorescent probe for the detection of AmpC beta-lactamase and the application in screening beta-lactamase inhibitors. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2020, 234, 118257.	3.9	0
14	Novel anti-Wolbachia drugs, a new approach in the treatment and prevention of veterinary filariasis?. Veterinary Parasitology, 2020, 279, 109057.	1.8	14
15	In vivo efficacy of the boron-pleuromutilin AN11251 against Wolbachia of the rodent filarial nematode Litomosoides sigmodontis. PLoS Neglected Tropical Diseases, 2020, 14, e0007957.	3.0	10
16	Pharmacokinetics of TKM-130803 in Sierra Leonean patients with Ebola virus disease: Plasma concentrations exceed target levels, with drug accumulation in the most severe patients. EBioMedicine, 2020, 52, 102601.	6.1	7
17	Pharmacokinetics of TKM-130803 in Ebola virus disease in Sierra Leonean subjects. Access Microbiology, 2020, 2, .	0.5	0
18	Pharmacokineticsâ€“Pharmacodynamics of High-Dose Ivermectin with Dihydroartemisininâ€“Piperazine on Mosquitocidal Activity and QT Prolongation (IVERMAL). Clinical Pharmacology and Therapeutics, 2019, 105, 388-401.	4.7	28

#	ARTICLE	IF	CITATIONS
19	In vivo kinetics of Wolbachia depletion by ABBV-4083 in <i>L. sigmodontis</i> adult worms and microfilariae. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007636.	3.0	27
20	Antimalarial activity of primaquine operates via a two-step biochemical relay. <i>Nature Communications</i> , 2019, 10, 3226.	12.8	94
21	Intra-individual effects of food upon the pharmacokinetics of rifampicin and isoniazid. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 416-424.	3.0	4
22	Intracellular PD Modelling (PDi) for the Prediction of Clinical Activity of Increased Rifampicin Dosing. <i>Pharmaceutics</i> , 2019, 11, 278.	4.5	4
23	Discovery of ABBV-4083, a novel analog of Tylosin A that has potent anti-Wolbachia and anti-filarial activity. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007159.	3.0	29
24	Preclinical development of an oral anti- <i>Wolbachia</i> macrolide drug for the treatment of lymphatic filariasis and onchocerciasis. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	67
25	Short-course, oral flubendazole does not mediate significant efficacy against <i>Onchocerca</i> adult male worms or <i>Brugia microfilariae</i> in murine infection models. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0006356.	3.0	16
26	Development of a High-Throughput Cytometric Screen to Identify Anti-Wolbachia Compounds: The Power of Public-Private Partnership. <i>SLAS Discovery</i> , 2019, 24, 537-547.	2.7	11
27	Boron-Pleuromutilins as Anti- <i>Wolbachia</i> Agents with Potential for Treatment of Onchocerciasis and Lymphatic Filariasis. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 2521-2540.	6.4	35
28	Intracellular Pharmacodynamic Modeling Is Predictive of the Clinical Activity of Fluoroquinolones against Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 64, .	3.2	3
29	Industrial scale high-throughput screening delivers multiple fast acting macrofilaricides. <i>Nature Communications</i> , 2019, 10, 11.	12.8	93
30	Human Direct Skin Feeding Versus Membrane Feeding to Assess the Mosquitocidal Efficacy of High-Dose Ivermectin (IVERMAL Trial). <i>Clinical Infectious Diseases</i> , 2019, 69, 1112-1119.	5.8	15
31	AWZ1066S, a highly specific anti- <i>Wolbachia</i> drug candidate for a short-course treatment of filariasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 1414-1419.	7.1	57
32	Population pharmacokinetics of artesunate and dihydroartemisinin in pregnant and non-pregnant women with uncomplicated <i>Plasmodium falciparum</i> malaria in Burkina Faso: an open label trial. <i>Wellcome Open Research</i> , 2019, 4, 45.	1.8	1
33	Population Pharmacokinetic Properties of Sulfadoxine and Pyrimethamine: a Pooled Analysis To Inform Optimal Dosing in African Children with Uncomplicated Malaria. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	18
34	Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperazine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 615-626.	9.1	99
35	Suboptimal Exposure to Anti-TB Drugs in a TBM/HIV+ Population Is Not Related to Antiretroviral Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 449-457.	4.7	13
36	The biological evaluation of fusidic acid and its hydrogenation derivative as antimicrobial and anti-inflammatory agents. <i>Infection and Drug Resistance</i> , 2018, Volume 11, 1945-1957.	2.7	26

#	ARTICLE	IF	CITATIONS
37	Potent Antimalarial 2-Pyrazolyl Quinolone <i>1</i> (<i>Q</i>) Inhibitors with Improved Drug-like Properties. ACS Medicinal Chemistry Letters, 2018, 9, 1205-1210.	2.8	28
38	Intra-host dynamics of co-infecting parasite genotypes in asymptomatic malaria patients. Infection, Genetics and Evolution, 2018, 65, 414-424.	2.3	18
39	Synthesis and profiling of benzylmorpholine 1,2,4,5-tetraoxane analogue N205: Towards tetraoxane scaffolds with potential for single dose cure of malaria. Bioorganic and Medicinal Chemistry, 2018, 26, 2996-3005.	3.0	11
40	Exploring pancreatic pathology in Plasmodium falciparum malaria patients. Scientific Reports, 2018, 8, 10456.	3.3	7
41	Short-Course, High-Dose Rifampicin Achieves Wolbachia Depletion Predictive of Curative Outcomes in Preclinical Models of Lymphatic Filariasis and Onchocerciasis. Scientific Reports, 2017, 7, 210.	3.3	65
42	A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance. Nature Communications, 2017, 8, 15159.	12.8	51
43	Genetic Determinants of the Pharmacokinetic Variability of Rifampin in Malawian Adults with Pulmonary Tuberculosis. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	28
44	Pharmacokinetic-Pharmacodynamic modelling of intracellular Mycobacterium tuberculosis growth and kill rates is predictive of clinical treatment duration. Scientific Reports, 2017, 7, 502.	3.3	30
45	Rational Design, Synthesis, and Biological Evaluation of Heterocyclic Quinolones Targeting the Respiratory Chain of <i>Mycobacterium tuberculosis</i> . Journal of Medicinal Chemistry, 2017, 60, 3703-3726.	6.4	39
46	Influence of the pfmdr1 Gene on In Vitro Sensitivities of Piperaquine in Thai Isolates of Plasmodium falciparum. American Journal of Tropical Medicine and Hygiene, 2017, 96, 16-0668.	1.4	5
47	Identification and prioritization of novel anti- <i>Wolbachia</i> chemotypes from screening a 10,000-compound diversity library. Science Advances, 2017, 3, eaao1551.	10.3	24
48	Albendazole and antibiotics synergize to deliver short-course anti- <i>Wolbachia</i> curative treatments in preclinical models of filariasis. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E9712-E9721.	7.1	47
49	Synthesis and structure-activity relationship of <i>N</i> ⁴ -benzylamine- <i>N</i> ² -isopropyl-quinazoline-2,4-diamines derivatives as potential antibacterial agents. RSC Advances, 2017, 7, 52227-52237.	3.6	12
50	Mechanisms of Antimalarial Drug Resistance. , 2017, , 629-647.		2
51	OptiMal-PK: an internet-based, user-friendly interface for the mathematical-based design of optimized anti-malarial treatment regimens. Malaria Journal, 2016, 15, 344.	2.3	1
52	A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children. British Journal of Clinical Pharmacology, 2016, 81, 679-687.	2.4	20
53	A Click Chemistry-Based Proteomic Approach Reveals that 1,2,4-Trioxolane and Artemisinin Antimalarials Share a Common Protein Alkylation Profile. Angewandte Chemie - International Edition, 2016, 55, 6401-6405.	13.8	76
54	A Click Chemistry-Based Proteomic Approach Reveals that 1,2,4-Trioxolane and Artemisinin Antimalarials Share a Common Protein Alkylation Profile. Angewandte Chemie, 2016, 128, 6511-6515.	2.0	19

#	ARTICLE	IF	CITATIONS
55	Gametocyte carriage in uncomplicated Plasmodium falciparum malaria following treatment with artemisinin combination therapy: a systematic review and meta-analysis of individual patient data. BMC Medicine, 2016, 14, 79.	5.5	104
56	Optimisation of the synthesis of second generation 1,2,4,5 tetraoxane antimalarials. Tetrahedron, 2016, 72, 6118-6126.	1.9	14
57	A simple breath test for tuberculosis using ion mobility: A pilot study. Tuberculosis, 2016, 99, 143-146.	1.9	30
58	Minocycline as a re-purposed anti-Wolbachia macrofilaricide: superiority compared with doxycycline regimens in a murine infection model of human lymphatic filariasis. Scientific Reports, 2016, 6, 23458.	3.3	35
59	Lymphocyte Perturbations in Malawian Children with Severe and Uncomplicated Malaria. Vaccine Journal, 2016, 23, 95-103.	3.1	23
60	Artemisinin activity-based probes identify multiple molecular targets within the asexual stage of the malaria parasites <i>Plasmodium falciparum</i> 3D7. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 2080-2085.	7.1	209
61	Efficacy and Safety of High-Dose Ivermectin for Reducing Malaria Transmission (IVERMAL): Protocol for a Double-Blind, Randomized, Placebo-Controlled, Dose-Finding Trial in Western Kenya. JMIR Research Protocols, 2016, 5, e213.	1.0	30
62	Baseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysis. Malaria Journal, 2015, 14, 359.	2.3	47
63	Clinical determinants of early parasitological response to ACTs in African patients with uncomplicated falciparum malaria: a literature review and meta-analysis of individual patient data. BMC Medicine, 2015, 13, 212.	5.5	61
64	A Quinoline Carboxamide Antimalarial Drug Candidate Uniquely Targets Plasmodia at Three Stages of the Parasite Life Cycle. Angewandte Chemie - International Edition, 2015, 54, 13504-13506.	13.8	12
65	2-Pyridylquinolone antimalarials with improved antimalarial activity and physicochemical properties. MedChemComm, 2015, 6, 1252-1259.	3.4	14
66	The effect of dose on the antimalarial efficacy of artemether-lumefantrine: a systematic review and pooled analysis of individual patient data. Lancet Infectious Diseases, The, 2015, 15, 692-702.	9.1	74
67	Reflections on the Nobel Prize for Medicine 2015 – The Public Health Legacy and Impact of Avermectin and Artemisinin. Trends in Parasitology, 2015, 31, 605-607.	3.3	35
68	Antimalarial 4(1H)-pyridones bind to the Q site of cytochrome <i>bc₁</i> . Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 755-760.	7.1	90
69	Carbamoyl Triazoles, Known Serine Protease Inhibitors, Are a Potent New Class of Antimalarials. Journal of Medicinal Chemistry, 2015, 58, 6448-6455.	6.4	17
70	Pharmacokinetics of Antituberculosis Drugs in HIV-Positive and HIV-Negative Adults in Malawi. Antimicrobial Agents and Chemotherapy, 2015, 59, 6175-6180.	3.2	34
71	The Nobel Prize in Medicine 2015: Two drugs that changed global health. Science Translational Medicine, 2015, 7, 316ed14.	12.4	7
72	Development and Validation of a High-Throughput Anti-Wolbachia Whole-Cell Screen: A Route to Macrofilaricidal Drugs against Onchocerciasis and Lymphatic Filariasis. Journal of Biomolecular Screening, 2015, 20, 64-69.	2.6	43

#	ARTICLE	IF	CITATIONS
73	Proteomics analysis of antimalarial targets of <i>Garcinia mangostana</i> Linn.. Asian Pacific Journal of Tropical Biomedicine, 2014, 4, 515-519.	1.2	2
74	The proliferating cell hypothesis: a metabolic framework for <i>Plasmodium</i> growth and development. Trends in Parasitology, 2014, 30, 170-175.	3.3	51
75	Pharmacokinetics of co-formulated mefloquine and artesunate in pregnant and non-pregnant women with uncomplicated <i>Plasmodium falciparum</i> infection in Burkina Faso. Journal of Antimicrobial Chemotherapy, 2014, 69, 2499-2507.	3.0	31
76	Metabolite footprinting of <i>Plasmodium falciparum</i> following exposure to <i>Garcinia mangostana</i> Linn. crude extract. Experimental Parasitology, 2014, 145, 80-86.	1.2	14
77	Effects of Dosage, Comorbidities, and Food on Isoniazid Pharmacokinetics in Peruvian Tuberculosis Patients. Antimicrobial Agents and Chemotherapy, 2014, 58, 7164-7170.	3.2	23
78	Rapid kill of malaria parasites by artemisinin and semi-synthetic endoperoxides involves ROS-dependent depolarization of the membrane potential. Journal of Antimicrobial Chemotherapy, 2014, 69, 1005-1016.	3.0	116
79	Reprint of "Pharmacokinetic modelling of the anti-malarial drug artesunate and its active metabolite dihydroartemisinin" Computer Methods and Programs in Biomedicine, 2014, 114, e14-e28.	4.7	1
80	Anti- <i>Wolbachia</i> drug discovery and development: safe macrofilaricides for onchocerciasis and lymphatic filariasis. Parasitology, 2014, 141, 119-127.	1.5	130
81	Diagnostics for schistosomiasis in Africa and Arabia: a review of present options in control and future needs for elimination. Parasitology, 2014, 141, 1947-1961.	1.5	63
82	Inhibitors of the <i>Plasmodium</i> Mitochondrial Respiratory Chain. , 2014, , 1-18.		1
83	Mitochondrial Electron Transport Chain of <i>Plasmodium falciparum</i> . , 2014, , 1-14.		0
84	An Endoperoxide-Based Hybrid Approach to Deliver Falcipain Inhibitors Inside Malaria Parasites. ChemMedChem, 2013, 8, 1528-1536.	3.2	32
85	Glutathione Transport: A New Role for PfCRT in Chloroquine Resistance. Antioxidants and Redox Signaling, 2013, 19, 683-695.	5.4	50
86	Synthesis and evaluation of the antimalarial, anticancer, and caspase 3 activities of tetraoxane dimers. Bioorganic and Medicinal Chemistry, 2013, 21, 7392-7397.	3.0	19
87	CRIMALDDI: platform technologies and novel anti-malarial drug targets. Malaria Journal, 2013, 12, 396.	2.3	15
88	Antimalarial pharmacology and therapeutics of atovaquone. Journal of Antimicrobial Chemotherapy, 2013, 68, 977-985.	3.0	147
89	Pharmacokinetic modelling of the anti-malarial drug artesunate and its active metabolite dihydroartemisinin. Computer Methods and Programs in Biomedicine, 2013, 112, 1-15.	4.7	4
90	The folate metabolic network of <i>Falciparum</i> malaria. Molecular and Biochemical Parasitology, 2013, 188, 51-62.	1.1	40

#	ARTICLE	IF	CITATIONS
91	Artemisinin- <i>Polypyrrole</i> Conjugates: Synthesis, DNA Binding Studies and Preliminary Antiproliferative Evaluation. <i>ChemMedChem</i> , 2013, 8, 709-718.	3.2	7
92	Antimalarial activity of isoquine against Kenyan <i>Plasmodium falciparum</i> clinical isolates and association with polymorphisms in <i>pfcr</i> and <i>pfmdr1</i> genes. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 786-788.	3.0	6
93	Plasma and Cerebrospinal Proteomes From Children With Cerebral Malaria Differ From Those of Children With Other Encephalopathies. <i>Journal of Infectious Diseases</i> , 2013, 208, 1494-1503.	4.0	22
94	Antitubercular pharmacodynamics of phenothiazines. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 869-880.	3.0	48
95	Targeting the mitochondrial electron transport chain of <i>Plasmodium falciparum</i> : new strategies towards the development of improved antimalarials for the elimination era. <i>Future Medicinal Chemistry</i> , 2013, 5, 1573-1591.	2.3	55
96	CRIMALDDI: a prioritized research agenda to expedite the discovery of new anti-malarial drugs. <i>Malaria Journal</i> , 2013, 12, 395.	2.3	2
97	Cytochrome b Mutation Y268S Conferring Atovaquone Resistance Phenotype in Malaria Parasite Results in Reduced Parasite <i>bc1</i> Catalytic Turnover and Protein Expression. <i>Journal of Biological Chemistry</i> , 2012, 287, 9731-9741.	3.4	77
98	Pharmacokinetics of Rifampin in Peruvian Tuberculosis Patients with and without Comorbid Diabetes or HIV. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2357-2363.	3.2	43
99	HDQ, a Potent Inhibitor of <i>Plasmodium falciparum</i> Proliferation, Binds to the Quinone Reduction Site of the Cytochrome <i>bc1</i> Complex. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3739-3747.	3.2	53
100	Death Is Associated with Complement C3 Depletion in Cerebrospinal Fluid of Patients with Pneumococcal Meningitis. <i>MBio</i> , 2012, 3, .	4.1	14
101	Pharmacokinetic modelling of the anti-malarial drug artesunate and its active metabolite dihydroartemisinin. <i>IFAC Postprint Volumes IPPV / International Federation of Automatic Control</i> , 2012, 45, 266-271.	0.4	0
102	The development of quinoloneesters as novel antimalarial agents targeting the <i>Plasmodium falciparum bc1</i> protein complex. <i>MedChemComm</i> , 2012, 3, 39-44.	3.4	34
103	Quantification of rifampicin in human plasma and cerebrospinal fluid by a highly sensitive and rapid liquid chromatographic-tandem mass spectrometric method. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012, 70, 523-528.	2.8	40
104	Identification, Design and Biological Evaluation of Bisaryl Quinolones Targeting <i>Plasmodium falciparum</i> Type II NADH:Quinone Oxidoreductase (PfNDH2). <i>Journal of Medicinal Chemistry</i> , 2012, 55, 1831-1843.	6.4	94
105	Identification, Design and Biological Evaluation of Heterocyclic Quinolones Targeting <i>Plasmodium falciparum</i> Type II NADH:Quinone Oxidoreductase (PfNDH2). <i>Journal of Medicinal Chemistry</i> , 2012, 55, 1844-1857.	6.4	51
106	Identification of Novel Antimalarial Chemotypes via Chemoinformatic Compound Selection Methods for a High-Throughput Screening Program against the Novel Malarial Target, PfNDH2: Increasing Hit Rate via Virtual Screening Methods. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 3144-3154.	6.4	23
107	A yeast expression system for functional and pharmacological studies of the malaria parasite Ca^{2+}/H^{+} antiporter. <i>Malaria Journal</i> , 2012, 11, 254.	2.3	7
108	Examination of the Cytotoxic and Embryotoxic Potential and Underlying Mechanisms of Next-Generation Synthetic Trioxolane and Tetraoxane Antimalarials. <i>Molecular Medicine</i> , 2012, 18, 1045-1055.	4.4	12

#	ARTICLE	IF	CITATIONS
109	Generation of quinolone antimalarials targeting the <i>Plasmodium falciparum</i> mitochondrial respiratory chain for the treatment and prophylaxis of malaria. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 8298-8303.	7.1	143
110	Comparison of the Reactivity of Antimalarial 1,2,4,5-Tetraoxanes with 1,2,4-Trioxolanes in the Presence of Ferrous Iron Salts, Heme, and Ferrous Iron Salts/Phosphatidylcholine. Journal of Medicinal Chemistry, 2011, 54, 6443-6455.	6.4	47
111	4-Aminoquinolines: Chloroquine, Amodiaquine and Next-Generation Analogues. , 2011, , 19-44.		10
112	Second generation analogues of RKA182: synthetic tetraoxanes with outstanding in vitro and in vivo antimalarial activities. MedChemComm, 2011, 2, 661.	3.4	28
113	Population Pharmacokinetics of Sulfadoxine and Pyrimethamine in Malawian Children With Malaria. Clinical Pharmacology and Therapeutics, 2011, 89, 268-275.	4.7	22
114	Global proteomic analysis of plasma from mice infected with Plasmodium berghei ANKA using two dimensional gel electrophoresis and matrix assisted laser desorption ionization-time of flight mass spectrometry. Malaria Journal, 2011, 10, 205.	2.3	11
115	Sequence and gene expression of chloroquine resistance transporter (pfcrt) in the association of in vitro drugs resistance of Plasmodium falciparum. Malaria Journal, 2011, 10, 42.	2.3	28
116	Antimalarial MannoXanes: Hybrid Antimalarial Drugs with Outstanding Oral Activity Profiles and A Potential Dual Mechanism of Action. ChemMedChem, 2011, 6, 1357-1361.	3.2	25
117	Synthesis and Antimalarial Activities of a Diverse Set of Triazole-Containing Furamide Analogues. ChemMedChem, 2011, 6, 2094-2108.	3.2	26
118	Synthesis and biological activities of 4-N-(anilinyln-[oxazolyl])-7-chloroquinolines (n=3 or 4) against Plasmodium falciparum in in vitro models. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 4512-4515.	2.2	19
119	The Molecular Basis of Folate Salvage in Plasmodium falciparum. Journal of Biological Chemistry, 2011, 286, 44659-44668.	3.4	46
120	Selective toxicity of dihydroartemisinin on human CD34+ erythroid cell differentiation. Toxicology, 2010, 276, 128-134.	4.2	27
121	A novel drug for uncomplicated malaria: Targeted high throughput screening (HTS) against the type II NADH:ubiquinone oxidoreductase (PfNDH2) of Plasmodium falciparum. Biochimica Et Biophysica Acta - Bioenergetics, 2010, 1797, 80.	1.0	0
122	Identification of a 1,2,4,5-Tetraoxane Antimalarial Drug-Development Candidate (RKA182) with Superior Properties to the Semisynthetic Artemisinins. Angewandte Chemie - International Edition, 2010, 49, 5693-5697.	13.8	111
123	Inhibiting Plasmodium cytochrome bc1: a complex issue. Current Opinion in Chemical Biology, 2010, 14, 440-446.	6.1	97
124	Design, synthesis and antimalarial/anticancer evaluation of spermidine linked artemisinin conjugates designed to exploit polyamine transporters in Plasmodium falciparum and HL-60 cancer cell lines. Bioorganic and Medicinal Chemistry, 2010, 18, 2586-2597.	3.0	51
125	Oral Activated Charcoal Prevents Experimental Cerebral Malaria in Mice and in a Randomized Controlled Clinical Trial in Man Did Not Interfere with the Pharmacokinetics of Parenteral Artesunate. PLoS ONE, 2010, 5, e9867.	2.5	11
126	Discovery of Potent Small-Molecule Inhibitors of Multidrug-Resistant <i>Plasmodium falciparum</i> Using a Novel Miniaturized High-Throughput Luciferase-Based Assay. Antimicrobial Agents and Chemotherapy, 2010, 54, 3597-3604.	3.2	46

#	ARTICLE	IF	CITATIONS
127	Association Between the pfm _{dr1} Gene and In Vitro Artemether and Lumefantrine Sensitivity in Thai Isolates of Plasmodium falciparum. American Journal of Tropical Medicine and Hygiene, 2010, 83, 1005-1009.	1.4	45
128	Proteomic Analysis of Cerebrospinal Fluid in Pneumococcal Meningitis Reveals Potential Biomarkers Associated with Survival. Journal of Infectious Diseases, 2010, 202, 542-550.	4.0	27
129	Modular Synthesis and in Vitro and in Vivo Antimalarial Assessment of C-10 Pyrrole Mannich Base Derivatives of Artemisinin. Journal of Medicinal Chemistry, 2010, 53, 633-640.	6.4	52
130	The Molecular Mechanism of Action of Artemisinin—The Debate Continues. Molecules, 2010, 15, 1705-1721.	3.8	474
131	Lymphocyte subsets in healthy Malawians: Implications for immunologic assessment of HIV infection in Africa. Journal of Allergy and Clinical Immunology, 2010, 125, 203-208.	2.9	30
132	Endoperoxide Carbonyl Falcipain 2/3 Inhibitor Hybrids: Toward Combination Chemotherapy of Malaria through a Single Chemical Entity. Journal of Medicinal Chemistry, 2010, 53, 8202-8206.	6.4	35
133	Rationale Design of Biotinylated Antimalarial Endoperoxide Carbon Centered Radical Prodrugs for Applications in Proteomics. Journal of Medicinal Chemistry, 2010, 53, 4555-4559.	6.4	29
134	Synthesis, in vitro and in vivo antimalarial assessment of sulfide, sulfone and vinyl amide-substituted 1,2,4-trioxanes prepared via thiol-olefin co-oxygenation (TOCO) of allylic alcohols. Organic and Biomolecular Chemistry, 2010, 8, 2068.	2.8	16
135	A novel drug for uncomplicated malaria: targeted high throughput screening (HTS) against the type II NADH:ubiquinone oxidoreductase (PfNdh2) of Plasmodium falciparum. Malaria Journal, 2010, 9, .	2.3	2
136	CRIMALDDI: a co-ordinated, rational, and integrated effort to set logical priorities in anti-malarial drug discovery initiatives. Malaria Journal, 2010, 9, 202.	2.3	6
137	Chlorproguanil—Dapsone—Artesunate versus Artemether—Lumefantrine: A Randomized, Double-Blind Phase III Trial in African Children and Adolescents with Uncomplicated Plasmodium falciparum Malaria. PLoS ONE, 2009, 4, e6682.	2.5	58
138	Role of Known Molecular Markers of Resistance in the Antimalarial Potency of Piperaquine and Dihydroartemisinin In Vitro. Antimicrobial Agents and Chemotherapy, 2009, 53, 1362-1366.	3.2	33
139	Could Proteomic Research Deliver the Next Generation of Treatments for Pneumococcal Meningitis?. Interdisciplinary Perspectives on Infectious Diseases, 2009, 2009, 1-11.	1.4	2
140	In Vivo and In Vitro Efficacy of Amodiaquine against Plasmodium falciparum in an Area of Continued Use of 4-Aminoquinolines in East Africa. Journal of Infectious Diseases, 2009, 199, 1575-1582.	4.0	23
141	Chlorproguanil—Dapsone—Artesunate versus Chlorproguanil—Dapsone: A Randomized, Double-Blind, Phase III Trial in African Children, Adolescents, and Adults with Uncomplicated Plasmodium falciparum Malaria. American Journal of Tropical Medicine and Hygiene, 2009, 81, 969-978.	1.4	28
142	<i>Plasmodium falciparum</i> and Dihydrofolate Reductase I164L Mutations in Africa. Antimicrobial Agents and Chemotherapy, 2009, 53, 1722-1723.	3.2	1
143	Chapter 17 Type II NADH: Quinone Oxidoreductases of Plasmodium Falciparum and Mycobacterium Tuberculosis. Methods in Enzymology, 2009, 456, 303-320.	1.0	34
144	Comparative preclinical drug metabolism and pharmacokinetic evaluation of novel 4-aminoquinoline anti-malarials. Journal of Pharmaceutical Sciences, 2009, 98, 362-377.	3.3	16

#	ARTICLE	IF	CITATIONS
145	Pharmacokinetics of chlorproguanil, dapson, artesunate and their major metabolites in patients during treatment of acute uncomplicated Plasmodium falciparum malaria. <i>European Journal of Clinical Pharmacology</i> , 2009, 65, 977-987.	1.9	13
146	Semi-synthetic and synthetic 1,2,4-trioxaquines and 1,2,4-trioxolaquines: synthesis, preliminary SAR and comparison with acridine endoperoxide conjugates. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 2038-2043.	2.2	64
147	Antitumour and antimalarial activity of artemisinin-acridine hybrids. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 2033-2037.	2.2	50
148	Parasites bearing a single copy of the multi-drug resistance gene (pfmdr-1) with wild-type SNPs predominate amongst Plasmodium falciparum isolates from Malawi. <i>Acta Tropica</i> , 2009, 111, 78-81.	2.0	22
149	Candidate Selection and Preclinical Evaluation of <i>N</i> - <i>tert</i> -Butyl Isoquine (GSK369796), An Affordable and Effective 4-Aminoquinoline Antimalarial for the 21st Century. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 1408-1415.	6.4	80
150	Mechanisms of Antimalarial Drug Resistance. , 2009, , 561-574.		1
151	Measurement of adherence, drug concentrations and the effectiveness of artemether-lumefantrine, chlorproguanil-dapsone or sulphadoxine-pyrimethamine in the treatment of uncomplicated malaria in Malawi. <i>Malaria Journal</i> , 2009, 8, 204.	2.3	59
152	Glycerol: An unexpected major metabolite of energy metabolism by the human malaria parasite. <i>Malaria Journal</i> , 2009, 8, 38.	2.3	47
153	Chloroquine resistance before and after its withdrawal in Kenya. <i>Malaria Journal</i> , 2009, 8, 106.	2.3	136
154	Synthesis, Antimalarial Activity, and Preclinical Pharmacology of a Novel Series of 4-Fluoro and 4-Chloro Analogues of Amodiaquine. Identification of a Suitable "Back-Up" Compound for <i>N</i> - <i>tert</i> -Butyl Isoquine. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 1828-1844.	6.4	56
155	An efficient route into synthetically challenging bridged achiral 1,2,4,5-tetraoxanes with antimalarial activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 1720-1724.	2.2	30
156	Design and synthesis of novel 2-pyridone peptidomimetic falcipain 2/3 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 4210-4214.	2.2	60
157	Piperidine dispiro-1,2,4-trioxane analogues. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 5804-5808.	2.2	27
158	Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir. <i>British Journal of Pharmacology</i> , 2008, 155, 875-883.	5.4	40
159	Pharmacokinetics and clinical efficacy of midazolam in children with severe malaria and convulsions. <i>British Journal of Clinical Pharmacology</i> , 2008, 66, 529-538.	2.4	24
160	Malaria-parasite mitochondrial dehydrogenases as drug targets: too early to write the obituary. <i>Trends in Parasitology</i> , 2008, 24, 9-10.	3.3	24
161	Recent highlights in antimalarial drug resistance and chemotherapy research. <i>Trends in Parasitology</i> , 2008, 24, 537-544.	3.3	80
162	Two-Step Synthesis of Achiral Dispiro-1,2,4,5-tetraoxanes with Outstanding Antimalarial Activity, Low Toxicity, and High-Stability Profiles. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 2170-2177.	6.4	78

#	ARTICLE	IF	CITATIONS
163	<i>Plasmodium falciparum</i> Strains Harboring Dihydrofolate Reductase with the I164L Mutation Are Absent in Malawi and Zambia Even under Antifolate Drug Pressure. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 3883-3888.	3.2	11
164	Drug-Regulated Expression of <i>Plasmodium falciparum</i> P-Glycoprotein Homologue 1: a Putative Role for Nuclear Receptors. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1438-1445.	3.2	7
165	Acridinediones: Selective and Potent Inhibitors of the Malaria Parasite Mitochondrial bc1 Complex. <i>Molecular Pharmacology</i> , 2008, 73, 1347-1355.	2.3	85
166	Sulfadoxine-Pyrimethamine-Based Combinations for Malaria: A Randomised Blinded Trial to Compare Efficacy, Safety and Selection of Resistance in Malawi. <i>PLoS ONE</i> , 2008, 3, e1578.	2.5	31
167	Open-Label Comparative Clinical Study of Chlorproguanil-Dapsone Fixed Dose Combination (Lapdap) Alone or with Three Different Doses of Artesunate for Uncomplicated <i>Plasmodium falciparum</i> Malaria. <i>PLoS ONE</i> , 2008, 3, e1779.	2.5	20
168	Molecular surveillance for drug-resistant <i>Plasmodium falciparum</i> malaria in Malawi. <i>Acta Tropica</i> , 2007, 102, 138-142.	2.0	33
169	Antimalarial drugs and pregnancy: safety, pharmacokinetics, and pharmacovigilance. <i>Lancet Infectious Diseases</i> , 2007, 7, 136-144.	9.1	136
170	Evidence for a Common Non-Heme Chelatable-Dependent Activation Mechanism for Semisynthetic and Synthetic Endoperoxide Antimalarial Drugs. <i>Angewandte Chemie - International Edition</i> , 2007, 46, 6278-6283.	13.8	116
171	Practical HPLC methods for the quantitative determination of common antimalarials in Africa. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 847, 231-236.	2.3	34
172	A rapid and sensitive HPLC-MS method for the detection of plasma and cellular rifampicin. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 857, 76-82.	2.3	34
173	Study on the biochemical basis of mefloquine resistant <i>Plasmodium falciparum</i> . <i>Experimental Parasitology</i> , 2007, 117, 141-148.	1.2	9
174	The malaria parasite type II NADH:quinone oxidoreductase: an alternative enzyme for an alternative lifestyle. <i>Trends in Parasitology</i> , 2007, 23, 305-310.	3.3	69
175	Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein. <i>Tuberculosis</i> , 2007, 87, 248-255.	1.9	119
176	Design and synthesis of orally active dispiro 1,2,4,5-tetraoxanes; synthetic antimalarials with superior activity to artemisinin. <i>Organic and Biomolecular Chemistry</i> , 2006, 4, 4431.	2.8	83
177	Malaria Chemotherapy. <i>Advances in Parasitology</i> , 2006, 61, 47-76.	3.2	36
178	PfCRT and the trans-vacuolar proton electrochemical gradient: regulating the access of chloroquine to ferriprotoporphyrin IX. <i>Molecular Microbiology</i> , 2006, 62, 238-251.	2.5	85
179	Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone. <i>British Journal of Clinical Pharmacology</i> , 2006, 61, 289-300.	2.4	23
180	Diels-Alder/thiol-olefin co-oxygenation approach to antimalarials incorporating the 2,3-dioxabicyclo[3.3.1]nonane pharmacophore. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 2991-2995.	2.2	19

#	ARTICLE	IF	CITATIONS
181	Pharmacokinetics of dihydroartemisinin following oral artesunate treatment of pregnant women with acute uncomplicated falciparum malaria. <i>European Journal of Clinical Pharmacology</i> , 2006, 62, 367-371.	1.9	95
182	Synthesis of 1,2,4-trioxepanes via application of thiol-olefin Co-oxygenation methodology. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 6124-6130.	2.2	13
183	Functional Characterization and Target Validation of Alternative Complex I of <i>Plasmodium falciparum</i> Mitochondria. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 1841-1851.	3.2	120
184	A Medicinal Chemistry Perspective on 4-Aminoquinoline Antimalarial Drugs. <i>Current Topics in Medicinal Chemistry</i> , 2006, 6, 479-507.	2.1	104
185	Population Pharmacokinetics of Artesunate and Dihydroartemisinin following Intra-Rectal Dosing of Artesunate in Malaria Patients. <i>PLoS Medicine</i> , 2006, 3, e444.	8.4	59
186	Low Levels of Pyrazinamide and Ethambutol in Children with Tuberculosis and Impact of Age, Nutritional Status, and Human Immunodeficiency Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 407-413.	3.2	120
187	Potent Antihematozoan Activity of Novel Bisthiazolium Drug T16: Evidence for Inhibition of Phosphatidylcholine Metabolism in Erythrocytes Infected with <i>Babesia</i> and <i>Plasmodium</i> spp. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 3381-3388.	3.2	27
188	Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. <i>Aids</i> , 2005, 19, 2097-2102.	2.2	84
189	Determination of midazolam and its major metabolite 1- α -hydroxymidazolam by high-performance liquid chromatography-electrospray mass spectrometry in plasma from children. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005, 821, 1-7.	2.3	23
190	Lewis acid catalysed rearrangements of unsaturated bicyclic [2.2.n] endoperoxides in the presence of vinyl silanes; access to novel Fenozan BO-7 analogues. <i>Tetrahedron Letters</i> , 2005, 46, 3029-3032.	1.4	11
191	Why has the dihydrofolate reductase 164 mutation not consistently been found in Africa yet?. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2005, 99, 341-346.	1.8	40
192	A critical role for PfCRT K76T in <i>Plasmodium falciparum</i> verapamil-reversible chloroquine resistance. <i>EMBO Journal</i> , 2005, 24, 2294-2305.	7.8	168
193	Defining the role of PfCRT in <i>Plasmodium falciparum</i> chloroquine resistance. <i>Molecular Microbiology</i> , 2005, 56, 323-333.	2.5	154
194	Comparative folate metabolism in humans and malaria parasites (part I): pointers for malaria treatment from cancer chemotherapy. <i>Trends in Parasitology</i> , 2005, 21, 292-298.	3.3	93
195	Comparative folate metabolism in humans and malaria parasites (part II): activities as yet untargeted or specific to <i>Plasmodium</i> . <i>Trends in Parasitology</i> , 2005, 21, 334-339.	3.3	59
196	Malaria parasite transporters as a drug-delivery strategy. <i>Trends in Parasitology</i> , 2005, 21, 299-301.	3.3	39
197	Enantiomeric 1,2,4-Trioxanes Display Equivalent in vitro Antimalarial Activity Versus <i>Plasmodium falciparum</i> Malaria Parasites: Implications for the Molecular Mechanism of Action of the Artemisinins. <i>ChemBioChem</i> , 2005, 6, 2048-2054.	2.6	49
198	Towards a proteomic definition of CoArtem action in <i>Plasmodium falciparum</i> malaria. <i>Proteomics</i> , 2005, 5, 1849-1858.	2.2	39

#	ARTICLE	IF	CITATIONS
199	In Vitro Synergy and Enhanced Murine Brain Penetration of Saquinavir Coadministered with Mefloquine. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 314, 1202-1209.	2.5	26
200	Coartem (Artemether+Lumefantrine) in Africa: The Beginning of the End?. <i>Journal of Infectious Diseases</i> , 2005, 192, 1303-1304.	4.0	61
201	Mutations Conferring Drug Resistance in Malaria Parasite Drug Transporters Pgh1 and PfCRT Do Not Affect Steady-State Vacuolar Ca ²⁺ . <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 4807-4808.	3.2	13
202	Current drug development portfolio for antimalarial therapies. <i>Current Opinion in Pharmacology</i> , 2005, 5, 473-478.	3.5	46
203	In vitro antimalarial drug susceptibility in Thai border areas from 1998-2003. <i>Malaria Journal</i> , 2005, 4, 37.	2.3	26
204	Therapy of Falciparum Malaria in Sub-Saharan Africa: from Molecule to Policy. <i>Clinical Microbiology Reviews</i> , 2004, 17, 612-637.	13.6	58
205	Functional Correlation of P-Glycoprotein Expression and Genotype with Expression of the Human Immunodeficiency Virus Type 1 Coreceptor CXCR4. <i>Journal of Virology</i> , 2004, 78, 12022-12029.	3.4	44
206	Therapeutic potential of folate uptake inhibition in Plasmodium falciparum. <i>Trends in Parasitology</i> , 2004, 20, 109-112.	3.3	28
207	Design and Synthesis of Endoperoxide Antimalarial Prodrug Models. <i>Angewandte Chemie - International Edition</i> , 2004, 43, 4193-4197.	13.8	56
208	Developmental toxicity of artesunate and an artesunate combination in the rat and rabbit. <i>Birth Defects Research Part B: Developmental and Reproductive Toxicology</i> , 2004, 71, 380-394.	1.4	126
209	Co(thd) ₂ : A Superior Catalyst for Aerobic Epoxidation and Hydroperoxysilylation of Unactivated Alkenes: Application to the Synthesis of Spiro-1,2,4-trioxanes.. <i>ChemInform</i> , 2004, 35, no.	0.0	0
210	Antimalarial and Antitumor Evaluation of Novel C-10 Non-Acetal Dimers of 10 ¹ -(2-Hydroxyethyl)deoxoartemisinin. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 1290-1298.	6.4	97
211	Application of Thiol-Olefin Co-oxygenation Methodology to a New Synthesis of the 1,2,4-Trioxane Pharmacophore. <i>Organic Letters</i> , 2004, 6, 3035-3038.	4.6	58
212	Evidence for a Central Role for PfCRT in Conferring Plasmodium falciparum Resistance to Diverse Antimalarial Agents. <i>Molecular Cell</i> , 2004, 15, 867-877.	9.7	157
213	Characterization of the choline carrier of Plasmodium falciparum: a route for the selective delivery of novel antimalarial drugs. <i>Blood</i> , 2004, 104, 3372-3377.	1.4	80
214	Comparison of chlorproguanil-dapsone with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: double-blind randomised controlled trial. <i>Lancet, The</i> , 2004, 363, 1843-1848.	13.7	97
215	Plasmodium falciparum: sacrificing membrane to grow crystals?. <i>Trends in Parasitology</i> , 2003, 19, 23-26.	3.3	59
216	Dangerous midwives and hemoglobin degradation: a response. <i>Trends in Parasitology</i> , 2003, 19, 199-200.	3.3	0

#	ARTICLE	IF	CITATIONS
217	Pentamidine uptake and resistance in pathogenic protozoa: past, present and future. Trends in Parasitology, 2003, 19, 232-239.	3.3	208
218	Antimalarial chemotherapy: young guns or back to the future?. Trends in Parasitology, 2003, 19, 479-487.	3.3	79
219	Co(thd)2: a superior catalyst for aerobic epoxidation and hydroperoxysilylation of unactivated alkenes: application to the synthesis of spiro-1,2,4-trioxanes. Tetrahedron Letters, 2003, 44, 8135-8138.	1.4	69
220	Artemisinins target the SERCA of Plasmodium falciparum. Nature, 2003, 424, 957-961.	27.8	904
221	Isoquine and Related Amodiaquine Analogues: A New Generation of Improved 4-Aminoquinoline Antimalarials. Journal of Medicinal Chemistry, 2003, 46, 4933-4945.	6.4	130
222	Heme Binding Contributes to Antimalarial Activity of Bis-Quaternary Ammoniums. Antimicrobial Agents and Chemotherapy, 2003, 47, 2584-2589.	3.2	67
223	The Digestive Food Vacuole of the Malaria Parasite Is a Dynamic Intracellular Ca ²⁺ Store. Journal of Biological Chemistry, 2003, 278, 27910-27915.	3.4	73
224	Acidification of the Malaria Parasite's Digestive Vacuole by a H ⁺ -ATPase and a H ⁺ -pyrophosphatase. Journal of Biological Chemistry, 2003, 278, 5605-5612.	3.4	107
225	Chemosensitization of Plasmodium falciparum by Probenecid In Vitro. Antimicrobial Agents and Chemotherapy, 2003, 47, 2108-2112.	3.2	57
226	Drug resistance in parasites. , 2003, , 397-432.		5
227	Biguanide-Atovaquone Synergy against Plasmodium falciparum In Vitro. Antimicrobial Agents and Chemotherapy, 2002, 46, 2700-2703.	3.2	22
228	Mechanism-Based Design of Parasite-Targeted Artemisinin Derivatives: Synthesis and Antimalarial Activity of New Diamine Containing Analogues. Journal of Medicinal Chemistry, 2002, 45, 1052-1063.	6.4	116
229	A Requiem for Chloroquine. Science, 2002, 298, 74-75.	12.6	57
230	Novel Short Chain Chloroquine Analogues Retain Activity Against Chloroquine Resistant K1 Plasmodium falciparum. Journal of Medicinal Chemistry, 2002, 45, 4975-4983.	6.4	121
231	Distribution of acridine orange fluorescence in Plasmodium falciparum-infected erythrocytes and its implications for the evaluation of digestive vacuole pH. Molecular and Biochemical Parasitology, 2002, 119, 301-304.	1.1	38
232	Further comments on the distribution of acridine orange fluorescence in P. falciparum-infected erythrocytes. Molecular and Biochemical Parasitology, 2002, 119, 311-313.	1.1	16
233	The pH of the Plasmodium falciparum digestive vacuole: holy grail or dead-end trail?. Trends in Parasitology, 2002, 18, 441-444.	3.3	32
234	Clinical status and implications of antimalarial drug resistance. Microbes and Infection, 2002, 4, 157-164.	1.9	84

#	ARTICLE	IF	CITATIONS
235	Synthesis, Antimalarial Activity, Biomimetic Iron(II) Chemistry, and in Vivo Metabolism of Novel, Potent C-10-Phenoxy Derivatives of Dihydroartemisinin. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 58-68.	6.4	92
236	Is reversal of chloroquine resistance ready for the clinic?. <i>Lancet, The</i> , 2001, 357, 904.	13.7	13
237	Optimisation of the allylsilane approach to C-10 deoxy carba analogues of dihydroartemisinin: synthesis and in vitro antimalarial activity of new, metabolically stable C-10 analogues. <i>Journal of the Chemical Society, Perkin Transactions 1</i> , 2001, , 2682-2689.	1.3	26
238	Diamidine Compounds: Selective Uptake and Targeting in <i>Plasmodium falciparum</i> . <i>Molecular Pharmacology</i> , 2001, 59, 1298-1306.	2.3	101
239	Regioselective Mukaiyama hydroperoxysilylation of 2-alkyl- or 2-aryl-prop-2-en-1-ols: application to a new synthesis of 1,2,4-trioxanes. <i>Tetrahedron Letters</i> , 2001, 42, 4569-4571.	1.4	54
240	The role of glutathione in the neurotoxicity of artemisinin derivatives in vitro. Abbreviations: AEM, artemether; DHA, dihydroartemisinin; and SOD, superoxide dismutase.. <i>Biochemical Pharmacology</i> , 2001, 61, 409-416.	4.4	39
241	P-glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?. <i>Aids</i> , 2001, 15, 1353-1358.	2.2	131
242	Relative contribution of cytochromes P-450 and flavin-containing monooxygenases to the metabolism of albendazole by human liver microsomes. <i>British Journal of Clinical Pharmacology</i> , 2000, 49, 313-322.	2.4	113
243	Molecular cloning of a gene encoding a 20S proteasome β^2 subunit from <i>Plasmodium falciparum</i> . <i>International Journal for Parasitology</i> , 2000, 30, 729-733.	3.1	7
244	Potent Enhancement of the Sensitivity of <i>Plasmodium falciparum</i> to Chloroquine by the Bisbenzylisoquinoline Alkaloid Cepharanthin. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 2706-2708.	3.2	25
245	Biomimetic Fe(II)-Mediated Degradation of Arteflene (Ro-42-1611). The First EPR Spin-Trapping Evidence for the Previously Postulated Secondary Carbon-Centered Cyclohexyl Radical. <i>Journal of Organic Chemistry</i> , 2000, 65, 1578-1582.	3.2	59
246	Definitive proof for a role of pfmdr 1 in quinoline resistance in <i>Plasmodium falciparum</i> . <i>Drug Resistance Updates</i> , 2000, 3, 80-81.	14.4	4
247	Cellular Uptake of Chloroquine Is Dependent on Binding to Ferriprotoporphyrin IX and Is Independent of NHE Activity in <i>Plasmodium falciparum</i> . <i>Journal of Cell Biology</i> , 1999, 145, 363-376.	5.2	155
248	Application of the TMSOTf—AgClO ₄ activator system to the synthesis of novel, potent, C-10 phenoxy derivatives of dihydroartemisinin. <i>Tetrahedron Letters</i> , 1999, 40, 9129-9132.	1.4	19
249	Na ⁺ /H ⁺ Antiporter, Chloroquine Uptake and Drug Resistance: Inconsistencies in a Newly Proposed Model. <i>Parasitology Today</i> , 1999, 15, 360-363.	3.0	13
250	Altered binding of chloroquine to ferriprotoporphyrin IX is the basis for chloroquine resistance. <i>Drug Resistance Updates</i> , 1999, 2, 97-103.	14.4	4
251	Novel, Potent, Semisynthetic Antimalarial Carba Analogues of the First-Generation 1,2,4-Trioxane Artemether. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 5487-5493.	6.4	58
252	New 4-Aminoquinoline Mannich Base Antimalarials. 1. Effect of an Alkyl Substituent in the 5-Position of the 4-Hydroxyanilino Side Chain. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 2747-2751.	6.4	58

#	ARTICLE	IF	CITATIONS
253	Chloroquine Uptake and Activity is Determined by Binding to Ferriprotoporphyrin IX in <i>Plasmodium falciparum</i> . Novartis Foundation Symposium, 1999, 226, 252-264.	1.1	9
254	A carbonyl oxide route to antimalarial yingzhaosu A analogues: Synthesis and antimalarial activity. Tetrahedron Letters, 1998, 39, 6065-6068.	1.4	61
255	A comparison of the phenomenology and genetics of multidrug resistance in cancer cells and quinoline resistance in <i>Plasmodium falciparum</i> . , 1998, 77, 1-28.		71
256	4-Aminoquinolines—Past, present, and future; A chemical perspective. , 1998, 77, 29-58.		242
257	The effect of 2,2'-substitution on the metabolism and toxicity of dapsone in vitro and in vivo. Environmental Toxicology and Pharmacology, 1998, 5, 145-153.	4.0	3
258	Access to Hematin: The Basis of Chloroquine Resistance. Molecular Pharmacology, 1998, 54, 170-179.	2.3	203
259	Relationship between Antimalarial Drug Activity, Accumulation, and Inhibition of Heme Polymerization in <i>Plasmodium falciparum</i> In Vitro. Antimicrobial Agents and Chemotherapy, 1998, 42, 682-686.	3.2	166
260	Central Role of Hemoglobin Degradation in Mechanisms of Action of 4-Aminoquinolines, Quinoline Methanols, and Phenanthrene Methanols. Antimicrobial Agents and Chemotherapy, 1998, 42, 2973-2977.	3.2	81
261	Enhanced in vitro neurotoxicity of artemisinin derivatives in the presence of haemin. Biochemical Pharmacology, 1997, 53, 5-10.	4.4	49
262	Synthesis, Antimalarial Activity, and Molecular Modeling of Tebuquine Analogues. Journal of Medicinal Chemistry, 1997, 40, 437-448.	6.4	105
263	The biomimetic iron-mediated degradation of arteflene (Ro-42-1611), an endoperoxide antimalarial: Implications for the mechanism of antimalarial activity. Tetrahedron Letters, 1997, 38, 4263-4266.	1.4	45
264	Mechanism-Based Design of Parasite-Targeted Artemisinin Derivatives: Synthesis and Antimalarial Activity of Benzylamino and Alkylamino Ether Analogues of Artemisinin. Journal of Medicinal Chemistry, 1996, 39, 4511-4514.	6.4	31
265	The role of drug accumulation in 4-aminoquinoline antimalarial potency. Biochemical Pharmacology, 1996, 52, 723-733.	4.4	88
266	Amodiaquine accumulation in <i>Plasmodium falciparum</i> as a possible explanation for its superior antimalarial activity over chloroquine. Molecular and Biochemical Parasitology, 1996, 80, 15-25.	1.1	78
267	The effect of fluorine substitution on the antimalarial activity of tebuquine. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 391-392.	2.2	10
268	In vitro selection of halofantrine resistance in <i>Plasmodium falciparum</i> is not associated with increased expression of Pgh1. Molecular and Biochemical Parasitology, 1996, 83, 35-46.	1.1	47
269	The effect of fluorine substitution on the haemotoxicity of Primaquine. Bioorganic and Medicinal Chemistry Letters, 1995, 5, 2309-2314.	2.2	9
270	The toxicity of artemisinin and related compounds on neuronal and glial cells in culture. Chemico-Biological Interactions, 1995, 96, 263-271.	4.0	75

#	ARTICLE	IF	CITATIONS
271	Chloroquine resistance of Plasmodium falciparum: further evidence for a lack of association with mutations of the pfmdr1 gene. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1994, 88, 694.	1.8	39
272	Relationship of global chloroquine transport and reversal of resistance in Plasmodium falciparum. Molecular and Biochemical Parasitology, 1994, 63, 87-94.	1.1	48
273	Clinical Pharmacokinetics in the Treatment of Tropical Diseases. Clinical Pharmacokinetics, 1994, 27, 150-165.	3.5	21
274	The Effect of Fluorine Substitution on the Metabolism and Antimalarial Activity of Amodiaquine. Journal of Medicinal Chemistry, 1994, 37, 1362-1370.	6.4	78
275	The potential of desipramine to reverse chloroquine resistance of Plasmodium falciparum is reduced by its binding to plasma protein. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1993, 87, 303.	1.8	21
276	Malaria chemotherapy: Resistance to quinoline containing drugs in Plasmodium falciparum. FEMS Microbiology Letters, 1993, 113, 1-7.	1.8	26
277	Effect of malaria infection and endotoxin-induced fever on phenacetin o-deethylation by rat liver microsomes. Biochemical Pharmacology, 1993, 45, 1235-1241.	4.4	20
278	Effect of malaria infection and endotoxin-induced fever on the metabolism of antipyrine and metronidazole in the rat. Biochemical Pharmacology, 1993, 45, 1243-1249.	4.4	14
279	Metabolism of gestodene in human liver cytosol and microsomes in vitro. Journal of Steroid Biochemistry and Molecular Biology, 1993, 46, 235-243.	2.5	17
280	Vacuolar acidification and chloroquine sensitivity in plasmodium falciparum. Biochemical Pharmacology, 1992, 43, 1219-1227.	4.4	49
281	Rapid chloroquine efflux phenotype in both chloroquine-sensitive and chloroquine-resistant Plasmodium falciparum. Biochemical Pharmacology, 1992, 44, 1317-1324.	4.4	81
282	Chloroquine sensitivity of Plasmodium falciparum in vivo in a savanna town in Cameroon. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1992, 86, 229-230.	1.8	5
283	Selective determination, in plasma, of artemether and its major metabolite, dihydroartemisinin, by high-performance liquid chromatography with ultraviolet detection. Biomedical Applications, 1992, 583, 131-136.	1.7	50
284	The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel. Contraception, 1991, 43, 305-316.	1.5	52
285	The effect of malaria infection on paracetamol disposition in the rat. Biochemical Pharmacology, 1991, 41, 1707-1711.	4.4	24
286	The effect of malaria infection on antipyrine metabolite formation in the rat. Biochemical Pharmacology, 1991, 41, 1264-1266.	4.4	13
287	Inter-individual variation in the metabolic activation of the antimalarial biguanides. Parasitology Today, 1991, 7, 120-123.	3.0	2
288	Effect of the progestogens, gestodene, 3-keto desogestrel, levonorgestrel, norethisterone and norgestimate on the oxidation of ethinyloestradiol and other substrates by human liver microsomes. Journal of Steroid Biochemistry and Molecular Biology, 1991, 38, 219-225.	2.5	49

#	ARTICLE	IF	CITATIONS
289	Rapid and sensitive method for the determination of albendazole and albendazole sulphoxide in biological fluids. <i>Biomedical Applications</i> , 1991, 566, 244-249.	1.7	31
290	Decomposition reactions of arteether, a semisynthetic derivative of qinghaosu (artemisinin). <i>Tetrahedron</i> , 1990, 46, 1871-1884.	1.9	11
291	Cytochrome P-450 activity in malarial parasites and its possible relationship to chloroquine resistance. <i>Molecular and Biochemical Parasitology</i> , 1990, 41, 251-257.	1.1	24
292	The safety and kinetics of intramuscular quinine in Malawian children with moderately severe falciparum malaria. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1990, 84, 482-487.	1.8	42
293	Lack of effect of halofantrine on hepatic drug metabolism in the rat in vivo and in vitro. <i>Biochemical Pharmacology</i> , 1990, 39, 1581-1586.	4.4	4
294	Determination of artelinic acid in blood plasma by high-performance liquid chromatography. <i>Biomedical Applications</i> , 1989, 495, 167-177.	1.7	4
295	Determination of arteether in blood plasma by high-performance liquid chromatography with ultraviolet detection after hydrolysis with acid. <i>Biomedical Applications</i> , 1989, 493, 125-136.	1.7	34
296	Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. <i>Clinical Pharmacology and Therapeutics</i> , 1989, 45, 72-79.	4.7	184
297	Determination of halofantrine and its principal metabolite desbutylhalofantrine in biological fluids by reversed-phase high-performance liquid chromatography. <i>Biomedical Applications</i> , 1988, 433, 339-344.	1.7	23
298	Mechanisms of chloroquine resistance in malarial chemotherapy. <i>Trends in Pharmacological Sciences</i> , 1988, 9, 241-246.	8.7	15
299	Carbaryl Metabolism is Inhibited by Ctmetidine in the Isolated Perfused Rat Liver and in Man. <i>Journal of Toxicology: Clinical Toxicology</i> , 1988, 26, 269-281.	1.5	2
300	The pharmacokinetics of (+)- and (âˆ—)-primaquine in the isolated perfused rat liver preparation. <i>Biochemical Pharmacology</i> , 1987, 36, 2238-2239.	4.4	8
301	The disposition of primaquine in the isolated perfused rat liver. <i>Biochemical Pharmacology</i> , 1987, 36, 3365-3369.	4.4	17
302	Quantitative determination of carbaryl and carbaryl metabolites by reversed-phase high-performance liquid chromatography. <i>Journal of Chromatography A</i> , 1987, 388, 462-466.	3.7	17
303	Determination of suramin in plasma by high-performance liquid chromatography. <i>Biomedical Applications</i> , 1985, 343, 224-228.	1.7	12
304	The effects of primaquine stereoisomers and metabolites on drug metabolism in the isolated perfused rat liver and in vitro rat liver microsomes. <i>Biochemical Pharmacology</i> , 1985, 34, 331-336.	4.4	27
305	The disposition of pyrimethamine in the isolated perfused rat liver. <i>Biochemical Pharmacology</i> , 1985, 34, 2193-2197.	4.4	12
306	The effect of variations in urinary pH on the pharmacokinetics of diethylcarbamazine.. <i>British Journal of Clinical Pharmacology</i> , 1981, 12, 807-812.	2.4	31

#	ARTICLE	IF	CITATIONS
307	Diethylcarbamazine disposition in patients with onchocerciasis. <i>Clinical Pharmacology and Therapeutics</i> , 1981, 30, 551-557.	4.7	25
308	Population pharmacokinetics of artesunate and dihydroartemisinin in pregnant and non-pregnant women with uncomplicated <i>Plasmodium falciparum</i> malaria in Burkina Faso: an open label trial. <i>Wellcome Open Research</i> , 0, 4, 45.	1.8	0